AMGN Stock Review
AMGN Stock Review
History of AMGN
AMGN stands for Amgen Inc., an American multinational biopharmaceutical company that specializes in discovering, developing, manufacturing, and distributing human therapies for diseases. The company was founded in 1980 by venture capitalist William K. Bowes Jr. and biomedical scientist Dennis J. Slamon. AMGN is headquartered in Thousand Oaks, California, with subsidiaries in over 30 countries. The company has a long and rich history in biotechnology and has been a pioneer in the field, with many of its products being the first of their kind on the market.
To learn more about the history of AMGN, please visit their official website at https://www.amgen.com/
Representative of AMGN
The current president and CEO of AMGN is Robert A. Bradway. Bradway has been with the company since 2006 and has held several executive positions before being appointed CEO in 2012. Under his leadership, AMGN has continued to expand its product pipeline and has made significant advancements in the field of biotechnology.
To learn more about Robert A. Bradway and his leadership at AMGN, please visit their official website at https://www.amgen.com/about/leadership/robert-a-bradway/
Vision of AMGN
AMGN’s vision is to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health and prolong life. The company is committed to developing innovative and effective treatments for some of the most challenging diseases, such as cancer, rheumatoid arthritis, and osteoporosis. AMGN strives to make a positive impact on the world by improving the lives of patients and their families.
To learn more about AMGN’s vision and mission, please visit their official website at https://www.amgen.com/about/values-mission-vision/
Corporate Information of AMGN
AMGN is a publicly-traded company on the NASDAQ stock exchange, under the ticker symbol “AMGN”. As of 2021, the company has a market capitalization of over $130 billion and employs approximately 24,000 people worldwide. In 2020, AMGN reported net sales of $25.4 billion and invested over $3 billion in research and development.
To learn more about AMGN’s financial and corporate information, please visit their official website at https://www.amgen.com/investors/financials/
Frequently Asked Questions about AMGN
What products does AMGN develop?
AMGN develops a wide range of human therapies for various diseases, including cancer, rheumatoid arthritis, osteoporosis, and cardiovascular disease. Some of the company’s most well-known products include Enbrel, Prolia, Xgeva, and Repatha.
Where is AMGN headquartered?
AMGN is headquartered in Thousand Oaks, California, USA.
When was AMGN founded?
AMGN was founded in 1980.
Conclusion
AMGN is a global leader in biopharmaceuticals, with a long and innovative history in developing groundbreaking therapies for patients. The company’s focus on science and biotechnology has led to many first-of-their-kind products on the market, and its commitment to serving patients has made it a trusted name in the healthcare industry. As AMGN continues to invest in research and development, it is poised to make even more significant contributions to the field of biotechnology and to the lives of patients around the world.